Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies

Figure 2 Modifiable and non-modifiable risk factors of non-alcoholic fatty liver disease and its progression to severe liver disease. Dashed arrows indicate factors that promote or predispose to disease. Among non-modifiable risk factors, most important genetic variants of nonalcoholic fatty liver disease are being extensively studied. Type 2 diabetes-associated hyperglycemia induces progression from nonalcoholic steatohepatitis to hepatic fibrosis and HCC. CV: Cardiovascular; HCC: Hepatocellular carcinoma; NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis.